Replies to post #80052 on Amarantus Bioscience Holdings Inc (AMBS)

[blackhawks]

Key points. AMBS's patents were upheld in court:

(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.

(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.

WIDELY known AND baked into current AMBS pps.

(8) Is more of a cautionary to any JV or buyout candidate to NOT overvalue MANF, as the clinical path, including the results from human clinical trials, is anything but certain.

[Greeny1]

It's all speculation. If the company doesn't deliver soon the price will continue to fall. great news may come out but if the stock is $.005 when that happens it won't be good for people buying now. Be lucky to break even. BOL.